Showing results (11-20 of 165) with videos related to
Sort By:
Pageof 17
Therapeutics and Clinical Risk Management|August 30, 2008
Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophyMischel G Neill, Rohan Shahani, Alexandre R ZlottaDrugs of Today (Barcelona, Spain : 1998)|March 10, 2009
Strategies to preserve prostate healthMischel G Neill, Sree Appu, Alexandre R ZlottaDiscovery Medicine|December 21, 2007
Pharmacotherapy for prostate cancer: the role of hormonal treatmentRohan Shahani, Neil E Fleshner, Alexandre R ZlottaCanadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 19, 2009
The management of BCG failure in non-muscle-invasive bladder cancer: an updateAlexandre R Zlotta, Neil E Fleshner, Michael A JewettExpert Review of Anticancer Therapy|July 1, 2008
The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasterideMireia Musquera, Neil E Fleshner, Antonio Finelli, et al.European Urology|June 9, 2005
Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or FinasterideAlexandre R Zlotta, Pierre Teillac, Jean Pierre Raynaud, et al.BJU International|March 24, 2009
Prostate cancer: a serious disease suitable for preventionJohn M Fitzpatrick, Claude Schulman, Alexandre R Zlotta, et al.Cancers|January 23, 2024
Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the LiteratureAndres Llano, Amy Chan, Cynthia Kuk, et al.BJU International|July 9, 2009
The fate of an unsatisfactory urine cytology test among patients with urothelial carcinomaMichael Ordon, Scott Boerner, Alexandre R Zlotta, et al.European Urology|August 6, 2002
Repeat prostate biopsy: who, how and when?. a reviewBob Djavan, Mesut Remzi, Claude C Schulman, et al.Pageof 17